Archimed agreed to acquire cardiovascular drug developer Esperion Therapeutics for $3.16 per share1
The transaction closed on May 1, 20261
Archimed is a healthcare-focused investor acquiring Esperion and its portfolio of cardio drugs2
The deal includes a potential contingent value right (CVR) sweetener for shareholders1
Esperion shares surged following the acquisition announcement2
Sources:
1. https://www.fiercepharma.com/pharma/healthcare-investor-archimed-pay-11b-take-esperion-and-its-roster-cardio-drugs-private
2. https://prismmarketview.com/esperion-shares-surge-on-1-1b-archimed-buyout-deal/